长春西汀联合阿托伐他汀对老年男性脑梗死病人颈动脉硬化疗效的研究

目的探讨长春西汀联合阿托伐他汀在老年男性脑梗死合并颈动脉粥样硬化病人中的临床效果及其对尿酸、碱性成纤维细胞生长因子(bFGF)、超敏C反应蛋白(hs-CRP)水平的影响。方法选取2017年1月至2018年5月于我院治疗的老年男性脑梗死合并颈动脉粥样硬化病人105例为研究对象,按照随机数字表法分为对照组( n = 52)和观察组(n=53)。对照组给予阿托伐他汀、阿司匹林肠溶片等常规治疗,观察组在对照组基础上加用长春西汀治疗,治疗12周后对病人临床效果进行评估,比较2组颈动脉相关指标、尿酸、bFGF、hs-CRP水平及用药安全性。结果治疗12周后,观察组颈动脉内膜厚度(IMT)、最大软斑块长轴、平均斑块数目及最大斑块体积指数均小于对照组,尿酸、bFGF及hs-CPR水平均低于对照组,差异均有统计学意义(P<0.05);2组不良反应的发生率差异无统计学意义( P > 0.05)。结论长春西汀联合阿托伐他汀用于老年男性脑梗死合并颈动脉粥样硬化病人,能改善颈动脉IMT、最大软斑块长轴、斑块数目及体积,降低尿酸及bFGF、hs-CRP水平,药物安全性较高,值得推广应用。

Clinical effects of vinpocetine combined with atorvastatin for elderly males with cerebral infarction complicated with carotid atherosclerosis

Objective To investigate the clinical effects of vinpocetine combined with atorvastatin in the elderly males with cerebral infarction complicated with carotid atherosclerosis, and to investigate the levels of uric acid, basic fibroblast growth factor(bFGF), high sensitivity C-reactive protein(hs-CRP). Methods A total of 105 elderly males with cerebral infarction complicated with carotid atherosclerosis who were treated from January 2017 to May 2018 were enrolled. All cases were divided into control group(n= 52) and observation group( n= 53) by random number table. The control group was treated with atorvastatin and aspirin enteric-coated tablets. The observation group was treated with vinpocetine on the basis of the control group. The clinical effect of the patients was evaluated after 12 weeks of treatment. The carotid artery related indexes and the levels of uric acid, bFGF, hs-CRP were detected and compared between the two groups. Results The intima-media thickness(IMT), the largest soft plaque long axis, the average plaque number and the maximum plaque volume index were significantly lower in the observation group than those in the control group 12 weeks after treatment( P < 0.05). The levels of uric acid, bFGF and hs-CRP were significantly lower in the observation group than those in the control group 12 weeks after treatment. There was no significant difference in the incidence of adverse reactions between the two groups( P > 0.05). Conclusions Vinpocetine combined with atorvastatin can improve the carotid artery related indicators, reduce the levels of uric acid and hs-CRP, bFGF in elderly males with cerebral infarction and carotid atherosclerosis. It is safe and worthy of popularization and application.